Please assess the completion status of the following clinical trial:

Trial Title: Immediate or Delayed Naturopathic Medicine in Combination With Neo-Adjuvant Chemotherapy for Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* 18 years or older~* Eastern Cooperative Oncology Group (ECOG) performance status of ≤1~* Biopsy proven diagnosis of invasive adenocarcinoma of the breast~* Recommendation for neoadjuvant chemotherapy.~* Left Ventricular Ejection Fraction (LVEF) assessment by multigated acquisition scan or echocardiogram within 3 months of entering study~* Blood counts:~* Absolute Neutrophil Count ≥1200 cells/mm\^3~* Platelet count ≥100,000/mm\^3~* Hemoglobin ≥10g/dL~* Serum creatinine ≤ Upper Limit of Normal (ULN) for the laboratory range~* Total bilirubin ≤ ULN for the laboratory range, unless the patient has an elevation \>ULN to 1.5 times the ULN resulting from Gilbert's disease or similar syndrome~* Alkaline phosphatase less than or equal to 2.5 x ULN; and~* Aspartate aminotransferase (AST) less than or equal to 1.5 x ULN for the laboratory range~* If skeletal pain present or alkaline phosphatase \>ULN (but less than or equal to 2.5x ULN), bone scan or Positron Emission Tomography (PET) scan must not demonstrate metastatic disease~* AST or alkaline phosphatase greater than ULN, no metastatic disease liver identified by CT, MRI or PET scan~* Able to swallow oral medication~* Willing to forego naturopathic treatment for the first 2 treatment cycles~* Willing to start and continue naturopathic interventions as prescribed~* Willing to forego the use of nutritional or botanical supplements during the study~Exclusion Criteria:~* Stage 4 disease~* Present treatment with Warfarin.~* Synchronous bilateral invasive breast cancer~* Treatment including radiation, chemotherapy, and/or targeted therapy for the currently diagnosed breast cancer prior to entering study~* Any sex hormonal therapy e.g. birth control, ovarian hormone replacement therapy, etc. during participation in the study)~* Continued therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulators~* Prior history of breast cancer, including Ductal Carcinoma In Situ (subjects with a history of Lobular Carcinoma In Situ are eligible)~* Prior therapy with chemotherapy or targeted therapy agents for any malignancy~* Cardiac disease that would preclude the use of the certain drugs. This includes but is not confined to:~* Active cardiac disease~* Angina pectoris requiring treatment~* Ventricular arrhythmias except controlled benign premature ventricular contractions~* Conduction abnormality requiring a pacemaker~* Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled by medication~* Clinical significant valvular disease~* History of cardiac disease~* Myocardial infarction~* Congestive heart failure~* Cardiomyopathy~* Uncontrolled hypertension, (blood pressure above 150/90 mm/Hg on antihypertensive treatment)~* History or current symptomatic interstitial pneumonitis or pulmonary fibrosis~* Sensory/motor neuropathy ≥ grade 2~* Malabsorption syndrome, ulcerative colitis, resection the stomach or small bowel, or other disease significantly affecting gastrointestinal function~* Other non-malignant systemic disease precluding treatment with study regimens or required follow up~* Contraindication of corticosteroids~* Administration of an investigational agent within 30 days prior to entering study.~* Administration of therapeutic doses of the supplements being studied including maitake, melatonin and Coenzyme Q10 in the previous 30 days.~* Administration of therapeutic doses of immune modulating botanicals in the previous 30 days.~* Pregnancy or lactation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Immediate and Continuous Dosing (Type: ACTIVE_COMPARATOR): Subjects will be dosed with Reishi mushroom extract, Coenzyme Q10 and Melatonin beginning with Cycle 1 Day 1 of their prescribed neoadjuvant chemotherapy.
- Delayed Dosing (Type: ACTIVE_COMPARATOR): Subjects will be dosed with Reishi mushroom extract, Coenzyme Q10 and Melatonin beginning with Cycle 3 Day 1 of their prescribed neoadjuvant chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility